Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT06610890
- Locations
- 🇨🇳
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Bioequivalence Test of Hemay005 Tablets
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 28
- Registration Number
- NCT06610903
- Locations
- 🇨🇳
Wuhan Central Hospital, Wuhan, Hubei, China
To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT06380153
- Locations
- 🇨🇳
Union Hospital of Tongji Medical College; Huazhong University of Science and Technology, Wuhan, Hubei, China
To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT06376474
- Locations
- 🇨🇳
Union Hospital of Tongji Medical College; Huazhong University of Science and Technology, Wuhan, Hubei, China
A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- First Posted Date
- 2023-11-24
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 162
- Registration Number
- NCT06145893
- Locations
- 🇨🇳
Affiliated hospital of Guilin Medical university, Guilin, Guangxi, China
🇨🇳Linyi People's Hospital, Linyi, Shandong, China
🇨🇳Second hospital of shanxi medical university, Taiyuan, Shanxi, China
A Study to Evaluate the Effects of Single and Multiple Doses of Hemay005 Tablets in Health Caucasian Adult Volunteers
- Conditions
- Healthy
- Interventions
- Drug: Hemay005 60 mg
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT05941247
- Locations
- 🇦🇺
Scientia Clinical Research Ltd, Randwick, New South Wales, Australia
A Study of Hemay005 in Adult With Atopic Dermatitis
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 79
- Registration Number
- NCT05769946
- Locations
- 🇨🇳
First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-03-01
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 51
- Registration Number
- NCT05749432
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis
- Conditions
- Moderate to Severe Ulcerative Colitis
- Interventions
- Drug: Hemay005 placebo tabletsDrug: Hemay005 tablets
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 92
- Registration Number
- NCT05486104
- Locations
- 🇨🇳
The Fourth Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
In Vivo Mass Balance Study of [14C]Hemay005
- Conditions
- Health Volunteer
- Interventions
- Drug: [14C]Hemay005
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 6
- Registration Number
- NCT05468645
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China